Re: Two phase 2 trials of the novel akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor targeted therapy: Editorial comment

Samir S. Taneja

doi:10.1016/j.juro.2012.08.168

Re: Two phase 2 trials of the novel akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor targeted therapy: Editorial comment

Samir S. Taneja

Biomedical Engineering

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	2147-2148
Number of pages	2
Journal	Journal of Urology
Volume	188
Issue number	6
DOIs	https://doi.org/10.1016/j.juro.2012.08.168
State	Published - Dec 2012

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.juro.2012.08.168

Cite this

@article{14373bb1e47545e481acc82b22e01def,

title = "Re: Two phase 2 trials of the novel akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor targeted therapy: Editorial comment",

author = "Taneja, {Samir S.}",

year = "2012",

month = dec,

doi = "10.1016/j.juro.2012.08.168",

language = "English (US)",

volume = "188",

pages = "2147--2148",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Re

T2 - Two phase 2 trials of the novel akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor targeted therapy: Editorial comment

AU - Taneja, Samir S.

PY - 2012/12

Y1 - 2012/12

UR - http://www.scopus.com/inward/record.url?scp=84869077602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869077602&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2012.08.168

DO - 10.1016/j.juro.2012.08.168

M3 - Comment/debate

C2 - 23141219

AN - SCOPUS:84869077602

SN - 0022-5347

VL - 188

SP - 2147

EP - 2148

JO - Journal of Urology

JF - Journal of Urology

IS - 6

ER -

Re: Two phase 2 trials of the novel akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor targeted therapy: Editorial comment

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this